drugset / Trial / NCT00480818

Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Young and Elderly Subjects

NCT00480818

Phase 1 Completed 80 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

To assess the safety and tolerability of ascending multiple oral doses of SAM-531, an investigational drug, in healthy young adult and elderly subjects.To assess the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of multiple oral doses of SAM-531 in healthy young adult and elderly subjects.

Timeline

Start
2006-09
Primary completion
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject CERLAPIRDINE Small molecule Oral

Indications